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AbstrACt
Purpose The Upper Gastrointestinal Cancer Registry 
(UGICR) was developed to monitor and improve the quality 
of care provided to patients with upper gastrointestinal 
cancers in Australia.
Participants It supports four cancer modules: pancreatic, 
oesophagogastric, biliary and primary liver cancer. The 
pancreatic cancer (PC) module was the first module to be 
implemented, with others being established in a staged 
approach. Individuals are recruited to the registry if they 
are aged 18 years or older, have received care for their 
cancer at a participating public/private hospital or private 
clinic in Australia and do not opt out of participation.
Findings to date The UGICR is governed by a 
multidisciplinary steering committee that provides clinical 
governance and oversees clinical working parties. The 
role of the working parties is to develop quality indicators 
based on best practice for each registry module, develop 
the minimum datasets and provide guidance in analysing 
and reporting of results. Data are captured from existing 
data sources (population-based cancer incidence 
registries, pathology databases and hospital-coded 
data) and manually from clinical records. Data collectors 
directly enter information into a secure web-based 
Research Electronic Data Capture (REDCap) data collection 
platform. The PC module began with a pilot phase, and 
subsequently, we used a formal modified Delphi consensus 
process to establish a core set of quality indicators for PC. 
The second module developed was the oesophagogastric 
cancer (OGC) module. Results of the 1 year pilot phases for 
PC and OGC modules are included in this cohort profile.
Future plans The UGICR will provide regular reports of 
risk-adjusted, benchmarked performance on a range of 
quality indicators that will highlight variations in care and 
clinical outcomes at a health service level. The registry 
has also been developed with the view to collect patient-
reported outcomes (PROs), which will further add to our 
understanding of the care of patients with these cancers.
IntroduCtIon
The five most common upper gastrointes-
tinal (UGI) cancers in Australia are pancreas, 
oesophagus, stomach, liver (hepatocellular 
carcinoma) and biliary cancers; the combined 
incidence is approximately 10 000, and there 
are around 7500 deaths annually.1 The 5-year 
relative survival rates of UGI cancers are 
among the worst of all tumour types: 9.8% 
in pancreas; 18.5% in liver; 20.1% in biliary; 
22% in oesophagus; and 30.3% in stomach.1 
The dismal prognosis of these cancers can be 
largely attributed to their presentation at an 
strengths and limitations of this study
 ► The Upper Gastrointestinal Cancer Registry is the 
first clinical quality registry (CQR) in Australia, de-
signed to capture information on upper gastrointes-
tinal (UGI) cancers with the aim to improve practice 
by monitoring and providing benchmarked reports to 
participating sites.
 ► We describe the development of a CQR for UGI can-
cers, including the establishment of governance, 
recruitment framework, clinical quality indicators, 
minimum data set, data access policy and reporting 
structure.
 ► This registry was developed as per the Australian 
Commission on Quality and Safety in Health Care’s 
(ACSQHC) Framework for Australian CQRs and fol-
lows ACSQHC’s Australian Operating Principles for 
CQRs and can be used as a model for researchers 
developing CQRs.
 ► The time-consuming and labour-intensive site gov-
ernance approval process in Australia is a major lim-
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advanced disease stage. Additionally, older age is a risk 
factor for mortality from these tumours, and significant 
cardiac and respiratory comorbidities may limit treat-
ment options. As a result, only 15% of pancreas, 43% of 
liver, 20% of oesophagus and 50% of stomach cancers are 
potentially resectable at diagnosis.2 3
Resection, with radical lymph node dissection where 
appropriate, remains the principal potentially curative 
therapy for all localised UGI cancers. Disease manage-
ment is almost invariably multimodal and may include 
chemotherapy and radiotherapy as neoadjuvant, adju-
vant or palliative therapy and the provision of optimal 
supportive care.4–8
The aggressive nature of these cancers and the 
complexity of treatment often decrease health-related 
quality of life.9 Advances in surgical techniques and 
perioperative care have resulted in operative mortality 
falling to less than 5% in major centres.10 However, 
surgery remains a morbid procedure with postoperative 
complications resulting in prolonged hospital admission, 
adversely impacting on overall quality of life and the ability 
to undergo any adjuvant therapies.11 In those surviving 
1–2 years following curative treatment, health-related 
quality of life generally recovers to baseline. However, 
there are still major challenges faced by survivors. For 
those having palliative or supportive therapy only, quality 
of life frequently deteriorates throughout the disease 
trajectory.9
Local or distant cancer recurrence occurs frequently 
following resection for all UGI cancers. A third of 
patients diagnosed with stomach12 and half of all 
patients diagnosed with oesophageal13 cancer develop 
recurrent disease within 2 years. In pancreatic cancer 
(PC), where only 10%–15% of tumours are considered 
resectable, the local recurrence rate ranges from 10% 
to 40% and distant recurrence is as high as 88%.14
There is evidence that variability exists in the manage-
ment and outcomes of UGI cancers. For example, 
not all patients are presented to a multidisciplinary 
team meeting15; there are disparities in the utilisation 
of surgical resection and associated disease-specific 
survival based on where patients live16; there is wide 
variation in histopathological assessment of margins 
and the proportion that have clear margins14; the dura-
tion of surgery, postoperative complication rates and 
their management differ between public and private 
hospitals17 18; administration of adjuvant chemotherapy 
or radiotherapy is variable, often due to morbidity 
associated with postoperative complications19; and the 
30-day postoperative mortality is lower in hospitals 
performing more resections each year.20 21 Patients with 
UGI cancers have significant unmet needs pertaining 
to quality of life, finance, relationships and family or 
caregiver distress; these are often exacerbated by a lack 
of understanding of the health system.22 23 In PC, over 
50% of participants (n=136) in an Australian-based 
study reported moderate to high unmet physical or 
psychological needs.24
Measuring quality of care with clinical quality registries 
(CQrs)
To identify, understand and reduce unwarranted clin-
ical variation and ensure that all patients receive optimal 
care, it is important to collect high-quality disease-specific 
data. CQRs support continuous improvements in patient 
outcomes by monitoring quality of care and providing 
risk-adjusted feedback to the relevant clinical community. 
These data describe patterns of treatment in order to iden-
tify variation and can provide a framework for research.25 
Successful implementation of CQRs has been achieved in 
a range of disciplines include trauma, cardiac, transplant 
and bariatric surgery,26 joint replacement27 and cancer 
care (eg, prostate).28
The Australian Commission on Safety and Quality in 
Health Care (ACSQHC) supports the development of 
CQRs in Australia through the provision of the national 
framework for CQRs.29 The framework details the neces-
sary principles, guidelines and standards for best practice 
design, build, operation and security of CQRs. A recent 
evaluation of the cost-effectiveness of CQRs determined 
that when funded sufficiently with robust operating proce-
dures, CQRs provide a substantial return on investment.30 
In prioritising the development of CQRs in Australia, 
the ACSQHC ranked the development of registries for 
high-burden cancers only behind those monitoring isch-
aemic heart disease and musculoskeletal disorders.31 
PC is ranked fourth as a high-burden cancer in terms of 
its impact on disability-adjusted life years behind lung, 
bowel and breast cancer.32 It was predicted to be the third 
leading cause of cancer deaths in the USA in 2018 and by 
2030 is predicted to be the second most common cause of 
cancer associated mortality.2
Although a number of generic population-based 
cancer registries exist, there are no CQRs specific to the 
five aforementioned UGI cancers. Disease-specific regis-
tries33 34 and audit databases35 provide much needed 
evidence about the management of patients with these 
cancers. However, little prospective data have been 
published from multi-institution databases and/or regis-
tries regarding the quality of UGI cancer care across the 
disease trajectory.
rationale for the upper Gastrointestinal Cancer registry 
(uGICr)
Improvements in cancer outcomes for patients with UGI 
cancer will understandably come through establishment 
of models of care that are informed by close attention to 
clinical and patient-reported quality measures and stan-
dardisation of treatment that comply with agreed best 
practice. Given the lack of Australian population-level 
data regarding patient outcomes from UGI cancers, it was 
considered that a registry established to monitor treat-
ment and outcomes of patients with cancers arising in the 
oesophagus, stomach, pancreas, liver and biliary system 
will improve management of these diseases. Furthermore, 
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Figure 1 UGICR governance structure. HCC, hepatocellular 
carcinoma; PROMs, patient reported outcome measures; 
UGI, upper gastrointestinal.
Figure 2 Registry recruitment schema. GI, gastrointestinal.
gaps remain regarding optimal care and management of 
these patient groups.4–8 36
The UGICR is a CQR established with the aims to:
1. Assess patterns of care and identify variations in clini-
cal and patient reported outcomes.
2. Benchmark performance and provide feedback to ser-
vice providers using a targeted quality improvement 
approach to drive improvements in current practice.
3. Provide confidence to public, clinician and wider 
stakeholders on the delivery of high-quality service.
4. Advance knowledge of best treatment protocols by fa-




The UGICR is a multicentre, population-based, non-in-
terventional prospective cohort study.
It was established in 2015 in Victoria and has since 
expanded to the state of New South Wales, Australia.
Governance
The UGICR is governed by a Steering Committee and, 
currently, two clinical working parties with the responsi-
bility of each outlined in figure 1. The Steering Committee 
performs in accordance with the Australian Framework 
for CQRs.29
A central research team provides operational oversights. 
A principal investigator at each participating hospital is 
responsible for ensuring that research activities under-
taken at their site are conducted in accordance with the 
human research ethics committee (HREC) approval, the 
research protocol, site registry agreements and related 
policy documentation. At each site, patients are identi-
fied for recruitment and data collection occurs.
registry design
The UGICR has a multimodular design with pancreatic, 
oesophagogastric (OG), liver and biliary cancer modules. 
Data are entered into Research Electronic Data Capture 
(REDCap), a secure web-based application, hosted and 
managed by Helix (Monash University).37 The registry 
was developed in REDCap, and all data are held securely 
on a Monash University server that has been accredited 
under the information security standard ISO27001.38
Participant recruitment and consent
The full recruitment schema is outlined in figure 2. Eligible 
patients are identified within each jurisdiction through 
state-based cancer registries or by individual health services. 
Eligibility criteria are listed in table 1. The UGICR uses an 
opt-out approach to minimise selection bias.39
Eligible participants are mailed an introductory letter 
explaining the study and an information booklet outlining 
details of the registry, its purpose, possible outcomes of 
the research and the opt-out process. Participants are 
given 2 weeks to opt out of the registry before their partic-
ipation is assumed, after which we commence collec-
tion of clinical and personal data covering diagnosis to 
end-of-life care. Patients can withdraw their consent from 
participation in the registry at any point by telephoning 
or emailing the UGICR office, as outlined in the partic-
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Table 1 Eligibility criteria
All modules
Inclusion 1. Patient has a confirmed primary pancreatic, oesophageal, gastric, liver, biliary or gall bladder cancer 
with some limited exclusions specified in each module (see below).
2. Patient has been assessed or received care at a participating public or private hospital or private 
clinician rooms.
3. Patient is 18 years of age or older at time of diagnosis.
4. Patient has a diagnosis date on or after 1 January 2016 (apart from one centre that commenced 
recruitment in November 2015).
Module specific


























Exclusion Upper third of oesophagus. Neuroendocrine neoplasms.
Lymphomas.
Mesenchymal tumours.





  Adenosquamous carcinoma.
  Squamous cell carcinoma.
Cholangiosarcoma.
Exclusion Distal bile duct. Neuroendocrine neoplasms.
Mesenchymal tumours.
Liver* Inclusion Liver. Hepatocellular carcinoma.




*Liver module eligibility criteria still to be finalised.
IPMN, intraductal papillary mucinous neoplasm.
where patients deemed eligible require an interpreter, 
have significant cognitive impairment or where there is 
evidence that the patient is deceased.
FIndInGs to dAte
data set
The first module developed was the PC module, which 
began with a pilot phase of approximately 1 year, during 
which we collected data for a provisional set of quality 
indicators in three Victorian sites from 2016 to 2017. The 
second module developed using a similar pilot phase was 
the OG module. Subsequently, we used a formal modi-
fied Delphi consensus process to establish a core set of 
quality indicators for PC. This process involved 19 PC care 
experts from three states in Australia. A detailed descrip-
tion of the methods of the modified Delphi process and 
the selected indicators has been published separately.40 
In addition, a review was undertaken of the Australian 
Optimal Care Pathways (OCP) for PC41 and OGC42 to 
ensure that indicators are aligned with the seven themes 
described in the OCP (prevention and early detection; 
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Table 2 PC Optimal Care Pathway (OCP) mapped to modified Delphi quality indicators
PC OCP OCP elements
Mapped quality indicators from modified Delphi 
consensus40






Step 2: Presentation, initial 
investigations and referral
2.1 Signs and symptoms.
2.2 Assessments by general 
practitioner or medical practitioner.
2.3 Referral.
 ► Documented baseline CA19-9 level before 
treatment.
 ► Documented ECOG and/or ASA at presentation.
 ► Time from referral to definitive treatment within 60 
days.
2.4, 3.5, 4.6, 5.4, 6.6 and 7.3
Support and communication
Nil





 ► Documented pancreatic protocol CT or MRI scan 
for diagnosis and/or staging.
 ► Operability of tumour is clearly defined and 
documented as either operable/resectable, 
borderline resectable, locally advanced 
(unresectable) or metastatic (unresectable).
 ► Disease management for all patients discussed at 
an MDT meeting.
3.4, 4.4, 5.3, 6.5 and 7.2
Research and clinical trials
 ► Number of patients included in a clinical trial.
3.1 and 3.2
Timeframe
 ► Time from referral to definitive treatment within 60 
days.
Step 4: Treatment 4.1 Treatment intent Nil
4.2.1 Surgery (curative)  ► All patients who did not undergo surgery should 
have a valid reason documented.
 ► Number of patients undergoing PC surgery in a 
level 1–4 hospital.
4.2.1 Chemotherapy or 
chemoradiation.
 ► Adjuvant chemotherapy administered following 
surgery or a reason documented for not 
undergoing treatment.
4.2.2 and 4.3
Treatment of unresectable PC/
palliative care.
 ► Chemotherapy±chemoradiation offered to 
patients with locally advanced disease, or a 
reason documented for not undergoing treatment.
 ► Number of patients who saw a medical or 
radiation oncologist or a reason documented for 
not doing so.
4.5 Complementary or alternative 
therapies.
Nil
Step 5: Care after initial treatment 
and recovery
5.1 Survivorship.
5.2 Post-treatment care planning.
 ► All patients having completed treatment followed 
up by a specialist every 3–6 months for up to 2 
years.Step 6: Managing recurrent, 
residual and metastatic disease
6.1 Signs and symptoms of 
recurrent, residual or metastatic 
disease.
Step 7: End-of-life-care 6.4 Palliative care.
7.1 Multidisciplinary palliative care.
 ► All patients with metastatic disease referred to (or 
seen by) palliative care specialist.
Some elements in each step of the pathway are overlapping. Elements 6.2 and 6.3 readdress steps 3 and 4. Please note: the purpose of 
this document is to provide a broad overview of the areas within the OCP that the developed PC quality indicators measure. Only the key 
indicators that map to the elements are listed.
ASA, American Society of Anesthesiologists (performance status); ECOG, Eastern Cooperative Oncology Group (performance status); MDT, 
Multidisciplinary Team.
staging and treatment planning; treatment; care after 
initial treatment and recovery; managing recurrent, 
residual or metastatic disease; and end-of-life care). An 
outline of this process for PC is provided in table 2. There 
are currently no clinical quality indicators in the UGICR 
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of PC. However, the UGICR is participating in a collab-
orative project, Symptom-UGI: Upper Gastrointestinal 
Cancer Symptom Study, to map the patient pathways from 
onset of symptoms to cancer diagnosis. Details of this 
study can be found within the UGICR website (https:// 
ugicr. org. au/ associated- studies/).
The minimum data set was established to enable quality 
indicators to be calculated. Data items and definitions 
were aligned with national specifications where appro-
priate, and a comprehensive data dictionary was devel-
oped for each module. The core data items are outlined 
in table 3.
The OGC module has been developed by the OGC 
working party following a literature review, and a 
consensus method was used to agree on the quality 
indicator set. The registry has future plans to begin the 
collection of patient-reported outcomes (PROs) and 
patient-reported experiences (PREs) to provide valuable 
patient perspectives. As an initial step, a systematic review 
evaluating patient-reported outcome measures (PROMs) 
in PC has been undertaken by the UGICR team to define 
which PROMs are most appropriate for this group of 
patients.
data collection
If the participant has not opted out of the registry, data 
collectors abstract diagnosis, surgical, pathology and 
treatment data directly from the participant’s electronic 
and/or hard copy medical records from participating 
sites or from clinician rooms. Data collection begins close 
to the time of recruitment with at least annual follow-up 
until end of life.
results from the pilot studies from the PC and oGC modules
The results of the pilot phase for both PC and OGC 
modules are displayed in table 4. Of the 123 participants 
eligible for the PC module and 189 for the OGC module, 
8 (6.5%) and 9 (4.8%) opted out of the registry, respec-
tively. Clinical stage at diagnosis was not well documented 
in both the PC module (n=80, 70%) and OGC cancer 
module (n=82, 46%) and is an area for future quality 
improvement. Around 20% of the pancreatic cohort 
received surgery as first treatment, which is broadly 
representative of surgical treatment in patients with PC.43 
Furthermore, 73 participants in the PC and 94 partici-
pants in the OGC module had documented reasons for 
no surgery. The pilot results for both modules identified 
areas for improving data completeness, definitions, items 
and structure of data collection forms. Following the 
pilot phase, the registry focused on improving these areas 
before expanding to other participating hospitals.
Population coverage
Population coverage in Victoria is based on data from the 
Victorian Cancer Registry. The population coverage in 
the pilot phase was 19% for the PC module and 11% for 
the OGC module. Current coverage is 73% for PC and 
55% for the OGC module. In New South Wales, data are 
currently only being collected on the PC module with an 
estimated population coverage of 55%.
reporting
The registry will produce risk-adjusted benchmarked 
reports that will feed back deidentified data to partic-
ipating sites on the associated quality indicators. To 
provide fair and meaningful benchmarked reports, 
we have undertaken a review of risk models to identify 
demographic and baseline clinical variables (focusing on 
those over which clinicians have no control, for example, 
age, sex and disease stage) that predict patient outcomes 
for the purposes of risk adjustment. The data from the 
registry will also permit validation of current predictive 
risk models and enable further refinement of these tools. 
Publicly available annual reports that provide an over-
view of quality of care and the registry’s activities will be 
published. A UGICR website (https:// ugicr. org. au/) has 
been developed to provide information about the registry 
to patients, clinicians and other stakeholders. This will be 
updated to include results as they become available.
strenGths And lIMItAtIons
The UGICR is Australia’s first UGI cancer CQR. The aims 
of the registry are to monitor quality of care, benchmark 
clinical and patient-reported outcomes against best prac-
tice and provide high-quality population-based data for 
clinical research. Registries such as the UGICR provide 
much needed real-world evidence outside the context of 
randomised control trials about disease epidemiology, 
treatment patterns, burden of illness, survival outcomes, 
clinical variation and treatment safety.44
In recent decades, there has been increasing integration 
of PROMs into cancer registries to collect outcomes such 
as overall quality of life, functional and psychosocial well-
being, lifestyle behaviours and supportive care needs.45 
Clinicians and patients may place different emphasis 
on symptom impacts and expectations from their treat-
ment.46 The collection of PROMs is an important step in 
understanding patients’ experience of their symptoms 
and management and the impact of the disease and its 
treatment on their quality of life. The UGICR will deter-
mine and integrate the most relevant PROMs for each 
UGI cancer type following thorough examination of the 
literature.
Through the accumulation of significant and consistent 
data on UGI cancers, the registry will assess how clinical 
management compares with best practice and communi-
cate this to clinicians through the PIs or relevant hospital 
departments. Furthermore, the UGICR provides a plat-
form for longer term clinical follow-up, randomised clin-
ical trials and substudies exploring treatment outcomes 
and linking outcomes to tumour tissue characteristics.
An important consideration is the maturity of each 
module before useful quality indicator reports can be 
provided to participating hospitals, as some UGI cancers 
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Table 4 PC and OGC module data from pilot data collection
Variable
PC module OGC module
n (%) n (%)
Recruited 115 180
  Recruited via invitation letter 88 (76.5) 120 (66.7)
  Recruited via waiver of consent 
(deceased)
27 (23.5) 60 (33.3)
Sex
  Male 56 (48.7) 132 (73.3)
  Female 59 (51.3) 48 (26.7)
Age at diagnosis (years)
  <50 6 (5.2) 11 (6.1)
  50–59 14 (12.2) 22 (12.2)
  60–69 30 (26.1) 54 (30.0)
  70–79 38 (33.0) 54 (30.0)
  ≥80 22 (19.1) 33 (18.3)
  Missing 5 (4.3) 6 (3.3)
Resectability at diagnosis
  Resectable 25 (21.7) 58 (32.2)
  Borderline resectable 3 (2.6) 11 (6.1)
  Unresectable 67 (58.3) 64 (35.6)
  Locally advanced (LA) 24 (20.9) 6 (3.3)
  Metastatic (Mets) 43 (37.4) 58 (32.2)
  Not documented 14 (12.2) –
  Unknown – 41 (22.8)
  Missing 6 (5.2) 6 (3.3)
Clinical stage at diagnosis
  I or II 5 (4.3) 33 (18.3)
  III – 7 (3.9)
  IV 18 (15.7) 50 (27.8)
  Complete TNM* not documented 80 (69.6) 82 (45.6)
  Missing 12 (10.4) 8 (4.4)
First treatment
  Neoadjuvant therapy 4 (3.5) 60 (33.3)
  Attempted or completed resection 
surgery
27 (23.5) 13 (7.2)
  Curative intent ChemoTx and/or RT – 7 (3.9)
  Palliative intent ChemoTx and/or RT 37 (32.2) 55 (30.6)
  No treatment 29 (25.2) 23 (12.8)
  Unknown – 16 (8.9)
  Missing 18 (15.7) 6 (3.3)
Reasons for no surgery†
  LA or Mets 62 60
  Advanced age 1 6
  Comorbidities 7 9
  Patient declined 1 12
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Variable
PC module OGC module
n (%) n (%)
  Performance status – 4
  Other reason 1 –
  Reason not documented 4 3
Participant data collection status
  Complete 51 (44.3) 107 (59.4)
  Incomplete 64 (55.7) 73 (40.6)
Data entry subform completeness
  Demographics 113 (98.2) 180 (100.0)
  Vital status and tumour recurrence 58 (50.4) 145 (80.6)
  Diagnosis details 97 (84.3) 165 (91.7)
  Biliary stents 94 (81.7) –
  Surgery 102 (88.7) 168 (93.3)
  Pathology of resection sample 102 (88.7) –
  Neoadjuvant therapy 104 (90.4) –
  Adjuvant therapy 98 (85.2) –
  Therapy for locally advanced disease 95 (82.6) –
  Therapy for metastatic disease 77 (67.0) –
  Other treatment and trials 80 (70.0) –
  Treatment summary – 167 (92.8)
  Restaging after neoadjuvant therapy – 167 (92.8)
  Chemotherapy details – 162 (90.0)
  Radiotherapy details – 163 (90.6)
  End-of-life details – 81 (45.0)
*TNM system of classification of cancer.
†Reason for no surgery: participants may have more than one reason documented.
ChemoTX, chemotherapy; RT, radiotherapy.
Table 4 Continued
cancers.1 The working groups in collaboration with statis-
ticians will determine an analysis plan for each indicator 
with due consideration to data completeness and risk 
adjustment methods.
Identified challenges
The UGICR has faced some key challenges affecting its 
establishment and implementation. The introduction 
of the National Mutual Acceptance (NMA) scheme has 
significantly streamlined the ethics process for all public 
hospitals in Australia, except in the Northern Territory, 
making the process to gain approval for CQRs more 
manageable. However, obtaining governance approval at 
each site continues to be both labour intensive and time 
consuming.47 48 Furthermore, separate HREC approval is 
frequently required to access data from private hospitals 
and clinics.
Funding is another challenge faced by CQRs. As with 
many healthcare initiatives, the financial burden can be a 
major impediment.25 Data from CQRs are held in positive 
regard by clinicians, health managers and government. 
However, further funding will be required to progress 
national rollout of the registry.
Other identified barriers include reluctance of some 
healthcare providers to supply source data, and poor 
interoperability between clinical information systems 
leading to duplication of data entry. Where data are of 
high quality, such as for diagnosis and procedure codes, 
administrative data is appropriate, but there are limited 
data for comorbidities and risk factors.49 While automa-
tion of data collection from existing data sources would 
be ideal, this is hampered by inconsistent documentation 
and a lack of standardisation.50
Collaboration
The UGICR aims to capture whole of population, real-
world data that monitors and aspires to improve the 
quality of care provided to patients with UGI cancers. 
The registry is currently recruiting hospitals to increase 
population capture and selecting the most relevant 
instruments for measuring PROs and PREs for inclusion 
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phase, and the liver module is to be developed. Monash 
University is the UGICR’s data custodian and is account-
able for the privacy, security and integrity of patient infor-
mation held within the registry. Participating sites can 
request a copy of their own patient-level data. Researchers 
may access registry data following a formal submission to 
the UGICR data custodian and approval by the UGICR 
Steering Committee. They are required to complete a 
request form detailing their research aims and methods, 
potential impact on healthcare, and provide evidence 
relevant HREC approval before deidentified data will 
be released. The registry will harness new opportunities 
for data linkage with technologies such as the electronic 
medical records and collaborate with existing data repos-
itories (eg, biomedical) to evolve and fulfil its aim of 
providing quality evidence.
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